ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "patient-reported outcome measures"

  • Abstract Number: 070 • 2020 Pediatric Rheumatology Symposium

    The Importance of the Patient Global Health Assessment of Disease Activity in Polyarticular Juvenile Idiopathic Arthritis

    Rebecca Trachtman1, Daniel J. Lovell 2, Rula Issa 1, Stephanie Pan 1, Karen Wilson 1 and Karen Onel 3, 1Icahn School of Medicine at Mount Sinai, New York, 2Cincinnati, 3Hospital for Special Surgery, New York

    Background/Purpose: Polyarticular juvenile idiopathic arthritis (pJIA) is a subtype of JIA wherein more than four joints are affected with arthritis; it is characterized by unpredictable…
  • Abstract Number: 104 • 2020 Pediatric Rheumatology Symposium

    Patients Perspectives on Living with a Systemic Autoinflammatory Disease: Impact on Quality of Life

    Mariana Correia Marques1, Nicole Tennermann 2, Sivia Lapidus 3, Grant Schulert 4, Jennifer Tousseau 2, Rashmi Sinha 5, Karen Durrant 6, Saskya Angevare 7 and Fatma Dedeoglu 8, 1Boston Children's Hospital, Boston, Massachusetts, 2, 3The Joseph M. Sanzari Children's Hospital, Hackensack Meridian Health, Maplewood, 4Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, 5Systemic JIA Foundation, Cincinnati, 6Autoinflammatory Alliance, San Francisco, 7Amersfoort, Netherlands, 8Boston Children's Hospital, Boston

    Background/Purpose: Systemic autoinflammatory diseases (SAIDs) encompass multiple clinical entities in which spontaneous inflammation occurs due to dysregulation of the innate immune response.  The variability in…
  • Abstract Number: 835 • 2019 ACR/ARP Annual Meeting

    High Baseline Patient’s Compared with Evaluator’s Global Assessment Is Associated with Lower Retention and Remission Rates of First TNF Inhibitor in Psoriatic Arthritis Patients – Data from the EuroSpA Research Collaboration Network

    Brigitte Michelsen1, Lykke Midtbøll Ørnbjerg 2, Herman Mann 3, Tore Kvien 4, Michael J. Nissen 5, Maria José Santos 6, Dan Nordström 7, Lennart Jacobsson 8, Ziga Rotar 9, Bjorn Gudbjornsson 10, Süleyman Serdar Koca 11, Catalin Codreanu 12, Manuel Pombo-Suarez 13, Irene van der Horst-Bruinsma 14, Anne Gitte Loft 15, Karel Pavelka 3, Eirik Kristianslund 16, Burkhard Moeller 17, Elsa Vieira-Sousa 18, Anna Mari Hokkanen 19, Ulf Lindström 20, Matija Tomsic 21, Thorvardur J Love 22, Abdurrahman Tufan 23, Ruxandra IONESCU 24, Carlos Sánchez-Piedra 25, Marleen van de Sande 26, Gary Macfarlane 27, Florenzo Iannone 28, Lise Hyldstrup 2, Mikkel Østergaard 29 and Merete Lund Hetland 30, 1Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Denmark/ Hospital of Southern Norway Trust, Kristiansand, Norway/ Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, 2Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Denmark, Copenhagen, Denmark, 3Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic, 4Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway, 5University Hospital Geneva, Geneva, Switzerland, 6Rheumatology department, Hospital Garcia de Orta, Almada, Portugal, 7Department of Medicine, ROB-FIN, Helsinki University Hospital and Helsinki University, Helsinki, Finland., Helsinki, Finland, 8Dept of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden,, Gothenburg, Sweden, 9UMC LJUBLJANA, DPT. OF RHEUMATOLOGY, LJUBLJANA, Slovenia, 10Centre for Rheumatology Research, Landspitali and Faculty of Medicine, University of Iceland, Reykjavik, Iceland, 11Fırat University School of Medicine Division of Rheumatology, Elazığ, Turkey, 12Center of Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania., Bucharest, Romania, 13Unit Research, Spanish Society of Rheumatology, Madrid, Spain, 14Amsterdam University Medical Center, Amsterdam, Netherlands, 15Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, Århus, Denmark, 16Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway., Oslo, Norway, 17University Hospital Bern, Bern, Switzerland, 18Rheumatology and Metabolic Bone Diseases, Hospital de Santa Maria - Centro Hospitalar Lisboa Norte, EPE | Rheumatology Research Unit, Instituto de Medicina Molecular - Faculty of Medicine, University of Lisbon, Lisbon Academic Medical Centre, Lisbon, Portugal,, Lisbon, Portugal, 19Helsinki University Hospital, Helsinki, Finland, 20University of Gothenburg, Gothenburg, Sweden, 21Department of Rheumatology, University Medical Center Ljubljana, Slovenia, Ljubljana, Slovenia, 22Faculty of Medicine, University of Iceland, Reykjavik, Iceland, 23Division of Rheumatology, Gazi University School of Medicine, Ankara, Turkey, Ankara, Turkey, 24SPITALUL CLINIC SFANTA MARIA, Bucharest, 25Research Unit, Spanish Society of Rheumatology, Madrid, Spain, 26Amsterdam UMC, Amsterdam, Netherlands, 27University of Aberdeen, Aberdeen, United Kingdom, 28Department of Emergency and Transplantation , Rheumatology Unit, University Hospital of Bari, Bari, Italy., Bari, Italy, 29Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark, 30DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark

    Background/Purpose: Discordance between baseline patient’s and evaluator’s global assessment of disease activity is common1 and may reduce the likelihood of remission following tumor necrosis factor…
  • Abstract Number: 2639 • 2019 ACR/ARP Annual Meeting

    Comparison of Patient Self-reported Data to Physician-driven Cohorts in Patients with Eosinophilic Granulomatosis with Polyangiitis

    Irena Doubelt1, Jason Springer 2, Tanaz Kermani 3, Antoine Sreih 4, Cristina Burroughs 5, David Cuthbertson 5, Simon Carette 1, Nader A. Khalidi 6, Curry L. Koening 7, Carol Langford 8, Carol A. McAlear 9, Larry W. Moreland 10, Paul Monach 11, Dianne Shaw 12, Philip Seo 13, Ulrich Specks 14, Kalen Young 15, Steven Ytterberg 14, Peter A. Merkel 16, Christian Pagnoux 1 and VCRC Vasculitis Clinical Research Consortium 17, 1Mount Sinai Hospital and University Health Network, Toronto, ON, Canada, 2Kansas University Medical Center, Kansas, MO, 3University of California Los Angeles, Los Angeles, CA, 4University of Pennsylvania, Philadelphia, PA, 5University of South Florida, Tampa, FL, 6McMaster University, Hamilton, ON, Canada, 7University of Utah Hospital, Salt Lake City, UT, 8Cleveland Clinic, Cleveland, OH, 9University of Pennsylvania - VCRC Project Manager, Philadelphia, PA, 10University of Pittsburgh, Pittsburgh, PA, 11Brigham and Women's Hospital, Boston, MA, 12Vasculitis Foundation, North Carolina, 13Johns Hopkins Medicine, Baltimore, MD, 14Mayo Clinic College of Medicine, Rochester, MN, 15Vasculitis Foundation, Kansas City, MO, 16Univeristy of Pennsylvania, Philadelphia, PA, 17University of Pennsylvania, Division of Rheumatology, philadelphia

    Background/Purpose: Aligning perspectives of patients and physicians in the diagnosis and management of diseases is imperative, particularly in rare, chronic diseases such as vasculitis. We…
  • Abstract Number: 838 • 2019 ACR/ARP Annual Meeting

    Are PROMIS Measures Associated with Minimal Disease Activity in Psoriatic Arthritis?

    Juliette Yedimenko1, Yuxuan Jin 2, Alexis Ogdie 3, Jessica Walsh 4, Jose Scher 5, Soumya Reddy 6 and M. Elaine Husni 1, 1Department of Rheumatologic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, 2Quantitative Health Science, Cleveland Clinic, Cleveland, OH, 3Department of Medicine and Rheumatology and Department of Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 4Division of Rheumatology, University of Utah, Salt Lake City, UT, 5Division of Rheumatology, New York University School of Medicine and NYU Langone Orthopedic Hospital, New York, NY, 6Division of Rheumatology, New York University School of Medicine, New York, NY

    Background/Purpose: Patient-reported outcomes (PROs) are an important part of clinical decision making and are frequently used in combination with objective measures of disease activity and…
  • Abstract Number: 2847 • 2019 ACR/ARP Annual Meeting

    Testing Different Thresholds for Patient Global Assessment in Defining ACR-EULAR Boolean Remission Criteria for RA

    Paul Studenic1, David Felson 2, Maarten de Wit 3, Farideh Alasti 4, Tanja Stamm 1, Josef Smolen 1 and Daniel Aletaha 1, 1Medical University of Vienna, Vienna, Austria, 2Boston University School of Medicine, Department of Rheumatology, Boston, 3Department of Medical Humanities, Amsterdam Public Health (APH), Amsterdam University Medical Centre, Amsterdam, Netherlands, 4Medical University of Vienna, Department of Medicine III, Division of Rheumatology, Vienna, Austria

    Background/Purpose: The patient global assessment (PGA) is a core set variable to assess RA disease activity. It is strongly linked to patient-reported pain and is…
  • Abstract Number: 1108 • 2019 ACR/ARP Annual Meeting

    Mobile Apps in Rheumatology: Review and Analysis Using the Mobile App Rating Scale (MARS)

    Johannes Knitza1, Koray Tascilar 2, Eva-Maria Messner 3, Marco Meyer 4, Diana Vossen 5, Almut Pulla 6, Philipp Bosch 7, Julia Kittler 8, Arnd Kleyer 1, Philipp Sewerin 9, Johanna Mucke 10, Isabell Haase 11, David Simon 12 and Martin Krusche 13, 1Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, 2Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, Erlangen, Bayern, Germany, 3Department for Clinical Psychology and Psychotherapy, Ulm University, Ulm, Germany, Ulm, Germany, 4Asklepios Klinik Altona, Rheumatologie, Klinische Immunologie, Nephrologie, Hamburg, Germany; German Society for Rheumatology (Working Group Young Rheumatology), Hamburg, Germany, 5Departement for Internal Medicine and Rheumatology, Rheinisches Rheumazentrum Meerbusch, St. Elisabeth-Hospital, Meerbusch, Germany; German Society for Rheumatology (Working Group Young Rheumatology), Meerbusch, Germany, 6Rheinisches Rheumazentrum Meerbusch, St. Elisabeth-Hospital, Meerbusch, Germany; German Society for Rheumatology (Working Group Young Rheumatology), Meerbusch, Germany, 7Department of Rheumatology and Immunology, Medical University Graz, Graz, Austria, Graz, Austria, 8Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany; German Society for Rheumatology (Working Group Young Rheumatology), Erlangen, Germany, 9Department of Rheumatology & Hiller Research Unit, University Hospital Düsseldorf,, Duesseldorf, Germany, 10Department and Hiller Research Unit of Rheumatology, Heinrich-Heine University Duesseldorf, Düsseldorf, Germany, 11Policlinic for Rheumatology & Hiller Research Centre for Rheumatology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, 12Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Bayern, Germany, 13Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin, Berlin, Germany; German Society for Rheumatology (Working Group Young Rheumatology), Berlin, Germany

    Background/Purpose: Mobile applications promise to facilitate the life of patients as well as physicians. In routine practice, however, rheumatology apps are largely unknown and little…
  • Abstract Number: 1209 • 2019 ACR/ARP Annual Meeting

    Patient-reported Outcome Measures in Systemic Lupus Erythematosus: Use in Clinical Practice – Preliminary Results from the Integrate Project

    Gamal Chehab1, Jutta Richter 2, Anna Kernder 1, Chiara Tani 3, Valentina Lorenzoni 4, Elena Elefante 3, Ilaria Palla 5, Sara Cannizzo 6, Salvatore Pirri 6, Isotta Triulzi 5, Leopoldo Trieste 5, Giuseppe Turchetti 5, Marta Mosca 3 and Matthias Schneider 7, 1Policlinic of Rheumatology and Hiller Research Unit Rheumatology, Heinrich-Heine-University, Duesseldorf, Germany, 2Department and Hiller Research Unit of Rheumatology, Heinrich-Heine University Duesseldorf, Duesseldorf, Nordrhein-Westfalen, Germany, 3Rheumatology Unit, Department of clinical and experimental medicine, University of Pisa, Pisa, Italy, 4Institute of Management , Scuola Superiore Sant'Anna, Pisa, Italy, 5Institute of Management, Scuola Superiore Sant'Anna, Pisa, Italy, 6Institute of Management, Scuola Superiore Sant'Anna, Pisa, Toscana, Italy, 7Policlinic for Rheumatology & Hiller Research Centre for Rheumatology, Heinrich-Heine-University Duesseldorf, Düsseldorf, Germany

    Background/Purpose: Due to improved mortality and morbidity in systemic lupus erythematosus (SLE), non-clinical indicators and outcomes, especially patient-reported ones, have become increasingly important in disease…
  • Abstract Number: 422 • 2019 ACR/ARP Annual Meeting

    The Impact of Adalimumab vs Placebo on Patient-Reported Outcomes and Utility Measures Among Patients with Moderately to Severely Active Psoriatic Arthritis

    Vibeke Strand1, Pankaj Patel 2, Naijun Chen 2 and Elizabeth M Lesser 3, 1Division of Immunology/Rheumatology, Stanford University, Stanford, CA, 2AbbVie Inc., North Chicago, IL, 3AbbVie Inc., North Chicago

    Background/Purpose: Physical function and health-related quality of life (HRQoL) are negatively impacted in patients (pts) with PsA, and treatment with conventional and biological (b) DMARDs…
  • Abstract Number: 1250 • 2019 ACR/ARP Annual Meeting

    Can Patient-Reported Outcomes and Disease Activity Scores Predict Patient Acceptable Symptom State in Adult-Onset Still’s Disease?

    Emre Bilgin 1, Timuçin Kaşifoğlu 2, Ahmet Omma 3, Cemal Bes 4, Muhammet Çınar 5, Hakan Emmungil 6, Orhan Küçükşahin 7, Servet Akar 8, Kenan Aksu 9, Fatih Yıldız 10, Nilüfer Kanıtez 11, Abdulsamet Erden 12, Sezin Turan 13, Ediz Dalkılıç 14, Selime Ermurat 15, Mutlu Hayran 16 and Umut Kalyoncu17, 1Hacettepe University Vasculitis Centre, Ankara, Turkey, Ankara, Turkey, 2Eskişehir Osmangazi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Eskişehir, Turkey, 3Ankara Numune Education and Research Hospital, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, 4University of Medical Sciences, İstanbul, Turkey, 5University of Medical Sciences, Ankara, Turkey, 6Trakya University, Edirne, Turkey, 7Liv Hospital, Ankara, Turkey, 8Izmir Katip Celebi University, Faculty of Medicine, Division of Rheumatology, İzmir, Turkey, 9Ege University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, İzmir, Turkey, 10Kahramanmaraş Sütçü İmam University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Kahramanmaraş, Turkey, 11Koç University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, İstanbul, Turkey, 12Ministry of Health Ankara City Hospital, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, 13Trakya University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Edirne, Turkey, 14Uludağ University, Bursa, Turkey, 15Uludağ University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Bursa, Turkey, 16Hacettepe University, Faculty of Medicine, Department of Preventive Oncology, Ankara, Turkey, 17Hacettepe University Department of Rheumatology, Ankara, Turkey

    Background/Purpose: Adult-onset Still’s disease (AOSD) is a rare, chronic and auto-inflammatory disorder with multisystemic involvement. Patient Acceptable Symptom State (PASS) is the highest level of…
  • Abstract Number: 424 • 2019 ACR/ARP Annual Meeting

    A Novel Patient-Reported Outcome Measure in IgG4-Related Disease: The Symptom Severity Index

    Tyler Harkness1, Karen Donelan 1, Xiaoqing Fu 1, Rachel Wallwork 1, Cory Perugino 1, John Stone 2 and Zachary Wallace 1, 1Massachusetts General Hospital, Boston, 2Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA

    Background/Purpose: IgG4-related disease (IgG4-RD) causes symptoms, the severity of which vary by organ involvement. The Responder Index (RI) captures physicians’ judgement of disease activity, but…
  • Abstract Number: 1352 • 2019 ACR/ARP Annual Meeting

    Effects of Upadacitinib on Patient-Reported Outcomes After 24 Weeks in Patients with Active Rheumatoid Arthritis and an Inadequate Response to Conventional Synthetic or Biologic Disease-Modifying Anti-Rheumatic Drugs: Results from SELECT-NEXT and SELECT-BEYOND Phase 3 Studies

    Martin Bergman1, Namita Tundia 2, Heidi Camp 2, Sebastian Meerwein 3, Casey Schlacher 2, Debbie Goldschmidt 4, Yan Song 5 and Vibeke Strand 6, 1Drexel University College of Medicine, Stockholm, Sweden, 2AbbVie Inc., North Chicago, IL, 3AbbVie GmbH Co. KG, Ludwigshafen, Germany, Wiesbaden, Germany, 4Analysis Group, Inc., New York, NY, 5Analysis Group, Inc., Boston, MA, 6Division of Immunology/Rheumatology, Stanford University, Stanford, CA

    Background/Purpose: Treatment with upadacitinib (UPA), a selective Janus kinase-1 (JAK-1) inhibitor, resulted in significant and clinically meaningful improvements in patient-reported outcomes (PROs) at Week 12…
  • Abstract Number: 428 • 2019 ACR/ARP Annual Meeting

    Assessing Meaningful Changes in Disease Activity as Clinical Trial Efficacy Measures for Cutaneous Lupus Erythematosus

    Srita Chakka1, Rebecca Krain 1, Sarah Ahmed 2, Josef Concha 1, Rui Feng 3 and Victoria Werth 4, 1University of Pennsylvania, Philadelphia, PA, 2Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA, 3University of Pennsylvania, Philadelphia, 4Corporal Michael J. Crescenz VAMC, Philadelphia, PA, USA and Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA

    Background/Purpose: To date, there are no approved treatments for cutaneous lupus erythematosus (CLE), a disease known to significantly burden a patient’s quality of life (QoL).…
  • Abstract Number: 1375 • 2019 ACR/ARP Annual Meeting

    Patient-Reported Outcomes of Upadacitinib versus Adalimumab Use in Patients with Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate: 26-Week Analysis of a Phase 3 Study

    Roy Fleischmann1, Martin Bergman 2, Namita Tundia 3, In-Ho Song 4, Jessica Suboticki 4, Yan Song 5 and Vibeke Strand 6, 1Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, 2Drexel University College of Medicine, Stockholm, Sweden, 3AbbVie Inc., North Chicago, IL, 4AbbVie Inc., North Chicago, IL, USA, North Chicago, IL, 5Analysis Group, Inc., Boston, MA, 6Division of Immunology/Rheumatology, Stanford University, Stanford, CA

    Background/Purpose: In patients with active rheumatoid arthritis (RA), 12-week treatment with upadacitinib (UPA) while on background MTX therapy resulted in significant and clinically meaningful improvements…
  • Abstract Number: 431 • 2019 ACR/ARP Annual Meeting

    Psychometric Properties of the Pediatric Patient-Reported Outcomes Measurement Information System (PROMIS®) Item Banks in a Dutch Clinical Sample of Children with Juvenile Idiopathic Arthritis

    Michiel Luijten 1, Caroline Terwee 2, Hedy van Oers 2, Mala Joosten 3, Merlijn van den Berg 2, Dieneke Schonenberg-Meinema 2, Koert Dolman 4, Rebecca Ten Cate 5, Leo Roorda 6, Martha Grootenhuis 3, Marion van Rossum7 and Lotte Haverman 2, 1Amsterdam University Medical Centers, Amsterdam, Noord-Holland, Netherlands, 2Amsterdam University Medical Centers, Amsterdam, Netherlands, 3Princess Maxima Centre for Pediatric Oncology, Utrecht, Netherlands, 4Onze Lieve Vrouwe Gasthuis West, Amsterdam, Netherlands, 5Leiden University Medical Centre, Leiden, Netherlands, 6Amsterdam Rehabilitation Research Center | Reade, Amsterdam, Netherlands, 7Amsterdam University Medical Centers, Amsterdam

    Background/Purpose: Patient-reported outcome measures (PROMs) are often used to include the patients perspective on treatment (outcome). However, the choice of PROMs is difficult, as there…
  • 1
  • 2
  • 3
  • …
  • 6
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology